Allelotype of Pancreatic Adenocarcinoma Using Xenograft Enrichment

Stephan A. Hahn, Albert B. Seymour, A. T.M.Shamsul Hoque, Mieke Schutte, Luis T. da Costa, Mark S. Redston, Craig L. Weinstein, Aryeh Fischer, Ralph H. Hruban, Scott E. Kern, Carlos Caldas, Scott E. Kern, Charles J. Yeo

Research output: Contribution to journalArticlepeer-review

325 Scopus citations


p53 and MTS1 are known to be mutationally inactivated in pancreatic adenocarcinoma. Other tumor suppressor genes are likely also to play a role. To define chromosomal arms which may harbor additional tumor suppressor genes, we performed an extensive allelotype on pancreatic cancer utilizing a xenograft enrichment technique. Eighty-eight percent (28β2) of primary tumors gave rise to xenografts. Eighteen cases were used in a PCR-based allelotype using 283 polymorphic markers, over 2800 informative assays, and an average coverage of 4.1 informative markers per chromosomal arm per case. Highly frequent allelic loss (>60%) was seen at chromosomes lp, 9p, 17p, and 18q. Moderately frequent allelic loss (40–60%) was seen at 3p, 6p, 6q, 8p, 10q, 12q, 13q, 18p, 21q, and 22q. The average fractional allelic loss was 036. Allelic and sequence stability was demonstrated among 64 parallel and second-passage xenografts derived from 12 cases of pancreatic adenocarcinoma with the ascertainment of over 3000 single alleles. The findings were confirmed in primary tumors. In only two instances were discrepancies revealed between the allelic loss data obtained from corresponding parallel xenografts, probably due to the xenografting of minor subpopulations, reflecting genetic heterogeneity of the primary tumor.

Original languageEnglish (US)
Pages (from-to)4670-4675
Number of pages6
JournalCancer Research
Issue number20
StatePublished - Oct 15 1995

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Allelotype of Pancreatic Adenocarcinoma Using Xenograft Enrichment'. Together they form a unique fingerprint.

Cite this